Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

QURE vs ELVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ELVN Captures Overall Composite Edge (36.2 SELL vs 48.9 HOLD), While QURE Leads 3–2 on Growth & Valuation Pillars

ELVN Overall Winner 6-Pillar Tally: QURE 3 – 2 ELVN (1 Tie) Matrix Metrics: QURE 4 – 5 ELVN

As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) captures the overall head-to-head institutional edge over uniQure N.V. (QURE) on higher Unified Composite conviction (36.2/100 SELL vs. 48.9/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while QURE wins 3–2 across the 6-pillar growth and valuation breakdown. QURE trades at $22.02 (27.9x Forward P/E, -994.0% operating margin) versus ELVN at $47.54 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While QURE currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. ELVN 36.2/100 SELL), ELVN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -994.0% operating margin) and revenue trajectory (+0.0% vs. +40.4% YoY).
  • Technical & Structure Timing Caution: QURE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9); meanwhile ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 53.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About QURE vs ELVN
QURE NASDAQ
uniQure N.V.
Pharmaceutical Preparations
$22.02
-7.52% 1D
Market Cap $1.7B
TTM Revenue $20M
Forward P/E 27.9x
Beta / 30D Vol 0.80β · 81% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 42.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -25.1%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $23.25 · SMA50: $29.05
ELVN NASDAQ Head-to-Head Winner
Enliven Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$47.54
-2.58% 1D
Market Cap $3.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 60% Vol
Unified Composite Score
36.2 / 100 SELL
Tech 15.0 Fund 44.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.2 · SMA20: $45.77 · SMA50: $46.19

6-Pillar Scorecard Institutional Category Breakdown (QURE 3 – 2 ELVN)

Columns: Metric · QURE · ELVN
1. Valuation Multiples QURE
Forward P/E 27.9x N/M
Trailing P/E 27.9x N/M
PEG Ratio N/M N/M
EV / Revenue 83.9x N/M
2. Growth & Scale QURE
Revenue Growth (YoY) +40.4% +0.0%
Earnings Growth (YoY) -18.2% +0.0%
TTM Revenue (USD) $20M N/A
Market Cap $1.7B $3.6B
3. Profitability & Quality ELVN
Gross Margin N/A N/A
Operating Margin -994.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -89.0% -16.8%
4. Balance Sheet & Cash Flow ELVN
Cash Generation (TTM) -$193M -$66M
Cash Flow Margin N/A N/A
Net Cash / Leverage $36M Net Cash $150M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning QURE
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 56.2% (<1st %ile) 46.9% (5th %ile)
Put/Call OI Skew 0.14x (Call-Skewed) 1.67x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: QURE (4) vs ELVN (5)
Institutional Metric QURE ELVN Criterion Row Edge
Market Capitalization
Scale
$1.7B $3.6B Larger Scale ELVN
Trailing P/E Ratio
Valuation
27.9x N/M Lower Multiple QURE
Forward P/E Ratio
Valuation
27.9x N/M Lower Multiple QURE
Revenue Growth (YoY)
Growth
+40.4% +0.0% Higher Growth QURE
Operating Margin (TTM)
Profitability
-994.0% 0.0% Higher Margin ELVN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-89.0% -16.8% Higher ROE ELVN
52-Week Range Position
Momentum
31% ($9–$52) 69% ($15–$62) Stronger Trend ELVN
Beta / 30D Volatility
Risk Regime
0.80β · 81% Vol 0.96β · 60% Vol Lower Realized Risk ELVN
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 36.2 / 100 (SELL) Higher Composite QURE
Trailing 12M Revenue (USD)
Operating Scale
$20M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 83.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$193M ($36M Net Cash) -$66M ($150M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ELVN +26.28 pp
QURE: +1.1% · ELVN: +27.38%
3M Horizon ELVN +32.66 pp
QURE: -53.52% · ELVN: -20.86%
6M Horizon ELVN +31.63 pp
QURE: -11.67% · ELVN: +19.96%
1Y Horizon ELVN +161.95 pp
QURE: -27.42% · ELVN: +134.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QURE vs ELVN. Trailing 12-month operating profitability (QURE -994.0% vs ELVN 0.0%) and valuation multiples (QURE 27.9x vs ELVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

QURE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross MarginN/A
Op. Margin-994.0%
ROE / Fwd P/E-89.0% · 27.9x
ELVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-16.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
QURE BREAKDOWN
102d in phase · OBV NEUTRAL
Current IV 56.2%
IV Percentile <1st %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact QURE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ELVN CONSOLIDATION
59d in phase · OBV NEUTRAL
Current IV 46.9%
IV Percentile 5th %ile
Put/Call OI Skew 1.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ELVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
QURE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -994.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ELVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ QURE vs ELVN Key Questions & Quantitative Answers

As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) captures the overall head-to-head institutional edge over uniQure N.V. (QURE) on higher Unified Composite conviction (36.2/100 SELL vs. 48.9/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while QURE wins 3–2 across the 6-pillar growth and valuation breakdown. QURE trades at $22.02 (27.9x Forward P/E, -994.0% operating margin) versus ELVN at $47.54 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While QURE currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. ELVN 36.2/100 SELL), ELVN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -994.0% operating margin) and revenue trajectory (+0.0% vs. +40.4% YoY). Technical & Structure Timing Caution: QURE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9); meanwhile ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 53.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

QURE leads the Growth & Scale pillar: QURE posts +40.4% YoY revenue growth and -18.2% YoY earnings growth on $20M TTM revenue (N/A gross margin, -994.0% operating margin), compared with ELVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, QURE generates $20M in USD-normalized revenue versus N/A for ELVN. In operating R&D and SG&A reinvestment, QURE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ELVN.

QURE screens cheaper on headline valuation multiples. QURE trades at 27.9x Forward P/E, 27.9x Trailing P/E, N/M PEG, and 83.9x EV/Revenue (unreported FCF margin), whereas ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against QURE (-89.0% ROE) versus ELVN (-16.8% ROE) capital efficiency.

In options market volatility and institutional positioning, QURE carries 56.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.80β · 81% Vol realized risk). By comparison, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.